Crossover RCT | Effects of SGLT2 inhibition on sodium in patients with chronic syndrome of inappropriate antidiuresis

Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial – Journal of the American Society of Nephrology

Commentary on Twitter

The syndrome of inappropriate antidiuresis (SIAD) is a major cause of hypotonic hyponatremia. This study shows the SGLT2 inhibitor empagliflozin is a promising new treatment for chronic SIAD-induced hyponatremia, possibly improving neurocognitive function https://t.co/U26RNmVM9j pic.twitter.com/8pH6xqSs7D

— JASN_News (@JASN_News) December 12, 2022